Abstract
Histone deacetylases (HDACs) regulate the expression and activity of numerous proteins involved in both cancer initiation and cancer progression. By removal of acetyl groups from histones, HDACs create a non-permissive chromatin conformation that prevents the transcription of genes that encode proteins involved in tumorigenesis. In addition to histones, HDACs bind to and deacetylate a variety of other protein targets including transcription factors and other abundant cellular proteins implicated in control of cell growth, differentiation and apoptosis. This review provides a comprehensive examination of the transcriptional and post-translational mechanisms by which HDACs alter the expression and function of cancer-associated proteins and examines the general impact of HDAC activity in cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1210610/MediaObjects/41388_2007_Article_BF1210610_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1210610/MediaObjects/41388_2007_Article_BF1210610_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1210610/MediaObjects/41388_2007_Article_BF1210610_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1210610/MediaObjects/41388_2007_Article_BF1210610_Fig4_HTML.gif)
Similar content being viewed by others
References
Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M et al. (2003). GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 23: 8429–8439.
Altenburg BC, Via DP, Steiner SH . (1976). Modification of the phenotype of murine sarcoma virus-transformed cells by sodium butyrate. Effects on morphology and cytoskeletal elements. Exp Cell Res 102: 223–231.
Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N et al. (2001). ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21: 6470–6483.
Ammanamanchi S, Brattain MG . (2004). Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 279: 32620–32625.
Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A et al. (2006). Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26: 7561–7574.
Augenlicht L, Shi L, Mariadason J, Laboisse C, Velcich A . (2003). Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. Oncogene 22: 4983–4992.
Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. (2005). Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729–26734.
Basseres DS, Baldwin AS . (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817–6830.
Bereshchenko OR, Gu W, Dalla-Favera R . (2002). Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32: 606–613.
Boffa LC, Vidali G, Mann RS, Allfrey VG . (1978). Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253: 3364–3366.
Boyes J, Byfield P, Nakatani Y, Ogryzko V . (1998). Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594–598.
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T . (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597–601.
Cabrero JR, Serrador JM, Barreiro O, Mittelbrunn M, Naranjo-Suarez S, Martin-Cofreces N et al. (2006). Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell 17: 3435–3445.
Campbell KJ, Rocha S, Perkins ND . (2004). Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 13: 853–865.
Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX . (2006). Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25: 5446–5461.
Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T et al. (2006). Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 26: 6859–6869.
Chen C, Edelstein LC, Gelinas C . (2000). The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687–2695.
Chen L, Fischle W, Verdin E, Greene WC . (2001). Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653–1657.
Chen LF, Mu Y, Greene WC . (2002). Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21: 6539–6548.
Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ et al. (2004). ETO protein of t(8;21) AML is a corepressor for BCL6 B-cell lymphoma oncoprotein. Blood 103: 1454–1463.
Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C et al. (2004a). Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627–638.
Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al. (2004b). Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390–392.
Crazzolara R, Johrer K, Johnstone RW, Greil R, Kofler R, Meister B et al. (2002). Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 119: 965–969.
Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427–436.
Duan H, Heckman CA, Boxer LM . (2005). Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608–1619.
Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW . (2003). The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 23: 607–619.
Feng L, Lin T, Uranishi H, Gu W, Xu Y . (2005). Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25: 5389–5395.
Follows GA, Tagoh H, Lefevre P, Hodge D, Morgan GJ, Bonifer C . (2003). Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J 22: 2798–2809.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400.
Ginsburg E, Salomon D, Sreevalsan T, Freese E . (1973). Growth inhibition and morphological changes caused by lipophilic acids in mammalian cells. Proc Natl Acad Sci USA 70: 2457–2461.
Glozak MA, Sengupta N, Zhang X, Seto E . (2005). Acetylation and deacetylation of non-histone proteins. Gene 363: 15–23.
Gregoretti IV, Lee YM, Goodson HV . (2004). Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17–31.
Gu W, Roeder RG . (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595–606.
Guenther MG, Barak O, Lazar MA . (2001). The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21: 6091–6101.
Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S et al. (2005). Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol 25: 5552–5566.
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN . (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177–189.
Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE . (1997). Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89: 341–347.
Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H . (2004). Functional regulation of GATA-2 by acetylation. J Leukoc Biol 75: 529–540.
Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH et al. (2006). Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66: 10770–10777.
Hernandez-Hernandez A, Ray P, Litos G, Ciro M, Ottolenghi S, Beug H et al. (2006). Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1. EMBO J 25: 3264–3274.
Ho WC, Dickson KM, Barker PA . (2005). Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 65: 4273–4281.
Hoberg JE, Popko AE, Ramsey CS, Mayo MW . (2006). IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol 26: 457–471.
Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K et al. (2006). Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5: 2203–2210.
Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M et al. (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395–404.
Huang X, Guo B . (2006). Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 66: 9245–9251.
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417: 455–458.
Hung HL, Lau J, Kim AY, Weiss MJ, Blobel GA . (1999). CREB-binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol 19: 3496–3505.
Inoue Y, Itoh Y, Abe K, Okamoto T, Daitoku H, Fukamizu A et al. (2007). Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 26: 500–508.
Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al. (2002). MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21: 6236–6245.
Jenuwein T, Allis CD . (2001). Translating the histone code. Science 293: 1074–1080.
Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ et al. (2004). Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 279: 29409–29417.
Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C et al. (2003). Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758–2766.
Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437–443.
Kim SH, Ahn S, Han JW, Lee HW, Lee HY, Lee YW et al. (2004). Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315: 964–970.
Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A et al. (2006). Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173: 533–544.
Kouzarides T . (2000). Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176–1179.
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601–607.
Kramer OH, Baus D, Knauer SK, Stein S, Jager E, Stauber RH et al. (2006). Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20: 473–485.
Krummel KA, Lee CJ, Toledo F, Wahl GM . (2005). The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 102: 10188–10193.
Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. (2002). Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672–2681.
Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN . (1997). Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349–356.
Lamonica JM, Vakoc CR, Blobel GA . (2006). Acetylation of GATA-1 is required for chromatin occupancy. Blood 108: 3736–3738.
Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S . (2002). Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277: 22045–22052.
Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H et al. (2002). The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8: 743–750.
Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD et al. (1999). p53 Sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19: 1202–1209.
Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W . (2004). Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 101: 2259–2264.
Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. (2001). Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137–148.
Luo RX, Postigo AA, Dean DC . (1998). Rb interacts with histone deacetylase to repress transcription. Cell 92: 463–473.
Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP et al. (1998). Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601–605.
Maison C, Bailly D, Peters AH, Quivy JP, Roche D, Taddei A et al. (2002). Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component. Nat Genet 30: 329–334.
Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D et al. (2002). In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21: 6820–6831.
McGarry LC, Winnie JN, Ozanne BW . (2004). Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene 23: 5284–5292.
Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ et al. (2000). The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol 20: 2075–2086.
Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA et al. (2004). Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520–527.
Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL et al. (2005). Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912–4922.
Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH . (2006). Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 20: 506–508.
Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC . (2006). Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 103: 7264–7269.
North BJ, Marshall BL, Borra MT, Denu JM, Verdin E . (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437–444.
Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K et al. (2001). Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61: 8331–8339.
Peinado H, Ballestar E, Esteller M, Cano A . (2004). Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24: 306–319.
Rampalli S, Pavithra L, Bhatt A, Kundu TK, Chattopadhyay S . (2005). Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol 25: 8415–8429.
Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin KL et al. (2006). RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene 25: 5777–5786.
Richon VM, Sandhoff TW, Rifkind RA, Marks PA . (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014–10019.
Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M et al. (2006). A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38: 566–569.
Roy S, Tenniswood M . (2007). Site-specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem 282: 4765–4771.
Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S et al. (2005). Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24: 4531–4539.
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A et al. (1998). DNA damage activates p53 through a phosphorylation–acetylation cascade. Genes Dev 12: 2831–2841.
Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC et al. (2006). RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25: 7646–7649.
Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani et al. (1999). Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940–34947.
Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K et al. (2007). An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25: 151–159.
Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. (2005). Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262–1266.
Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL . (2006). Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311: 844–847.
Simonsson M, Kanduri M, Gronroos E, Heldin CH, Ericsson J . (2006). The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. J Biol Chem 281: 39870–39880.
Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY et al. (2005). Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264–268.
Subramanian C, Opipari AW, Bian X, Castle VP, Kwok RP . (2005). Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 4842–4847.
Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS et al. (2006). Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841–851.
Tang Y, Luo J, Zhang W, Gu W . (2006). Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827–839.
Taunton J, Hassig CA, Schreiber SL . (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408–411.
Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW et al. (2006). SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 20: 1256–1261.
Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159.
Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S et al. (2002). Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295: 1726–1729.
Wang R, Cherukuri P, Luo J . (2005). Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 280: 11528–11534.
Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC . (2003). Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem 278: 25568–25576.
Watamoto K, Towatari M, Ozawa Y, Miyata Y, Okamoto M, Abe A et al. (2003). Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene 22: 9176–9184.
Wen YD, Perissi V, Staszewski LM, Yang WM, Krones A, Glass CK et al. (2000). The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci USA 97: 7202–7207.
Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. (2002). Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982–7992.
Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V, Shi Y . (2005). Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. Mol Cell 18: 483–490.
Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548–13558.
Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M et al. (2006). MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 119: 1850–1857.
Yamagata T, Mitani K, Oda H, Suzuki T, Honda H, Asai T et al. (2000). Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. EMBO J 19: 4676–4687.
Yamaguchi Y, Kurokawa M, Imai Y, Izutsu K, Asai T, Ichikawa M et al. (2004). AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 279: 15630–15638.
Yang G, Thompson MA, Brandt SJ, Hiebert SW . (2007). Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 26: 91–101.
Yang WM, Inouye C, Zeng Y, Bearss D, Seto E . (1996). Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci USA 93: 12845–12850.
Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. (2004). Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369–2380.
Yuan ZL, Guan YJ, Chatterjee D, Chin YE . (2005). Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269–273.
Zhang Y, Gilquin B, Khochbin S, Matthias P . (2006). Two catalytic domains are required for protein deacetylation. J Biol Chem 281: 2401–2404.
Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S et al. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22: 1168–1179.
Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y et al. (2006). Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26: 2782–2790.
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M . (2004). Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455–463.
Acknowledgements
We apologize to all investigators whose works were not cited in this article due to space limitations. Work in our laboratory is supported by grants from the National Institutes of Health and an endowment from the Kaul Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Glozak, M., Seto, E. Histone deacetylases and cancer. Oncogene 26, 5420–5432 (2007). https://doi.org/10.1038/sj.onc.1210610
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210610
Keywords
This article is cited by
-
In utero and postnatal exposure to Foeniculum vulgare and Linum usitatissimum seed extracts: modifications of key enzymes involved in epigenetic regulation and estrogen receptors expression in the offspring’s ovaries of NMRI mice
BMC Complementary Medicine and Therapies (2023)
-
Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth
Cell Death & Disease (2023)
-
An antioxidant ameliorates allergic airway inflammation by inhibiting HDAC 1 via HIF-1α/VEGF axis suppression in mice
Scientific Reports (2023)
-
The role and application of transcriptional repressors in cancer treatment
Archives of Pharmacal Research (2023)
-
Characteristics and mechanisms of latency-reversing agents in the activation of the human immunodeficiency virus 1 reservoir
Archives of Virology (2023)